YOU DESERVE A BETTER LIFE WITHOUT PAIN!
Chronic pain and neuropathic pain are indications for which there is high need in the clinic, and as many experts put it boldly recently, “… the lack of evidence for the outcomes of most of the treatments providers do for patients” is one of the preeminent crises in pain management today. Indeed, many patients suffering from neuropathic conditions have pain that is refractory to existing treatments. In this context, palmitoylethanolamide (PEA), an endogenous fatty acid amide, is emerging as a novel agent in the treatment of pain and inflammation.
Happy Biopharma Inc. is pleased to introduce NEO-PAIN RELIEF™ an innovative and effective formula with P.E.A (Palmitoylethanolamide), a patented ingredient for addressing chronic inflammation without side effects. Now available in Canada.
Collectively, over 3000 research studies have confirmed that palmitoylethanolamide act as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain.
These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, post-herpetic neuralgia, and vaginal pains. Probably due to the fact that PEA is an endogenous modulator as well as a compound in food, such as eggs and milk, no serious side effects have been reported, nor have drug–drug interactions.
For more information visit us at